Indo Borax buys 64.26% of Kronox for ₹246 cr

Deal announcement and why it matters

Indo Borax & Chemicals has moved to expand its portfolio by acquiring a controlling stake in specialty chemical manufacturer Kronox Lab Sciences Limited. The decision was cleared by Indo Borax’s Board of Directors at a meeting held on August 20, 2026. The transaction is structured as a share purchase agreement for a majority stake, followed by a mandatory open offer to public shareholders under India’s takeover rules. The acquisition, if completed as outlined, would give Indo Borax control and voting rights well above the 25% threshold that triggers an open offer. The consideration for the negotiated promoter stake is ₹246.12 crore, paid in cash through electronic transfer. The news places focus on takeover compliance, offer pricing, and what changes in control could mean for a listed chemical manufacturer.

Board approval and execution of the share purchase agreement

Indo Borax’s board approved the execution of the share purchase agreement on August 20, 2026. The agreement covers the purchase of 2.38 crore equity shares of Kronox Lab Sciences. These shares are being acquired from the company’s promoters: Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal. The negotiated price under the promoter deal is ₹103.22 per share. The aggregate consideration for this block is ₹246.12 crore, as stated in the announcement. The stake being acquired represents 64.26% of Kronox’s total paid-up equity share capital, giving Indo Borax a controlling position.

Deal structure: acquirer, promoters, and cash settlement

The acquisition is positioned as a promoter stake sale through a share purchase agreement. Zenrock Chemicals Private Limited (ZCPL) is participating in the deal as a person acting in concert with Indo Borax. The announcement specifies that the entire consideration for both the private agreement and the open offer will be paid in cash via electronic transfer. This matters because it clarifies funding form and settlement method, which can be relevant for transaction certainty and timelines. The structure also makes clear that Indo Borax is not just making a market purchase but is changing control through a negotiated transfer. The scale of the promoter block means post-transaction governance and voting control would shift to the acquirer.

Mandatory open offer under SEBI SAST Regulations

Because Indo Borax’s acquisition would take control and exceed the 25% voting rights threshold, it triggers a mandatory open offer under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Indo Borax, along with ZCPL as the person acting in concert, will make an open offer to public shareholders. The open offer is for up to 95.7 lakh equity shares, representing approximately 25.79% of Kronox’s voting share capital. The offer price has been set at ₹157.27 per equity share, determined in accordance with SAST regulations. The requirement is referenced under Regulation 3(1) and Regulation 4 of the SAST Regulations, as noted in the source text.

Key numbers at a glance

Price context: open offer price vs current market price

The source text states the current price of Kronox Lab Sciences Ltd as ₹186.19. Against that, the open offer price is ₹157.27 per share. The promoter deal price is ₹103.22 per share for the negotiated block. These three numbers reflect distinct transaction contexts: a negotiated control transaction with promoters, a regulated open offer price for public shareholders, and the prevailing market price at the time cited. The disclosure also underlines that the open offer price is determined as per SAST regulations, rather than being freely negotiated in the same way as a promoter block.

About Kronox Lab Sciences: business and incorporation

Kronox Lab Sciences Ltd was incorporated in 2008, according to the information provided. The company manufactures high purity fine inorganic chemicals, phosphate, and metallic chemicals. The text also lists use cases and end applications such as ingredients in agrochemical formulations, personal care products, refining agents in metal refineries, and ingredients in animal health products, among others. These details place Kronox in the specialty and high purity chemicals segment, where product quality and consistent specifications often matter for downstream industries. The acquisition therefore represents a control change in a manufacturer operating across multiple industrial and consumer-linked chemical applications.

IPO background and earlier disclosures

Kronox came to the market through an initial public offer that is described as an offer for sale. The text states that on June 6, 2024, the company issued 95,70,000 equity shares of face value ₹10 each and raised ₹130.15 crore through offer for sale. The offer price mentioned is ₹136 per equity share. The IPO timeline included an anchor investor offer price of ₹136 per share, with the anchor bid opening and closing on May 31, 2024. The bid or offer period opened on June 3, 2024 and closed on June 5, 2024, and trading was stated to commence on Monday, June 10, 2024 on NSE and BSE.

Other company updates referenced in the text

The source also references that Kronox Lab Sciences received approvals for Unit-IV construction at Dahej. Separately, it mentions a dividend of ₹0.5 per share. There is also a line referencing a window period: “January 01, 2025 till, after 48 hours of announcement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2024.” The text includes an earlier reference dated 26-May-2026 related to disclosure under SEBI takeover regulations. While these items are not directly part of the acquisition terms, they provide context that the company has had prior regulatory disclosures and corporate actions noted in public information.

Market impact and what investors typically track next

In the near term, the confirmed market-moving elements are the change in control through the promoter stake sale, and the open offer process for public shareholders. For investors, the key factual markers from the announcement are the stake size, the number of shares involved, the offer size, and the two disclosed transaction prices. The mention that consideration will be paid entirely in cash via electronic transfer clarifies payment method for both the SPA and the open offer. The open offer is explicitly linked to SEBI’s SAST framework, which sets procedural requirements for timelines and disclosures. Investors also tend to monitor whether any additional filings, approvals, or detailed public announcement documents follow, as implied by the inclusion of statutory references and the “public announcement for information purposes only” style text.

Conclusion

Indo Borax’s board-approved plan to acquire 64.26% of Kronox Lab Sciences for ₹246.12 crore sets up a clear change of control, backed by a promoter share purchase agreement and a SEBI-mandated open offer. The open offer is for up to 95.7 lakh shares, or about 25.79% of voting share capital, at ₹157.27 per share, with cash payment via electronic transfer. Kronox, incorporated in 2008, operates in high purity and specialty inorganic chemicals and has been listed following its 2024 offer for sale IPO. The next confirmed step embedded in the structure is the execution and completion process for the SPA and the required open offer to public shareholders under the SAST Regulations.